Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001493152-19-013333
Filing Date
2019-08-26
Accepted
2019-08-26 06:09:48
Documents
7
Effectiveness Date
2019-08-26

Document Format Files

Seq Description Document Type Size
1 formdefa14a.htm DEFA14A 32530
2 proxy_001.jpg GRAPHIC 258838
3 proxy_002.jpg GRAPHIC 330739
4 proxy_003.jpg GRAPHIC 124285
5 proxy_004.jpg GRAPHIC 82048
6 proxy_005.jpg GRAPHIC 339155
7 proxy_006.jpg GRAPHIC 277015
  Complete submission text file 0001493152-19-013333.txt   1977672
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51353 | Film No.: 191050451
SIC: 7389 Services-Business Services, NEC